Scaffold hopping based designing of selective ALDH1A1 inhibitors to overcome cyclophosphamide resistance: synthesis and biological evaluation-Reference-Cited by-同舟云学术

Scaffold hopping based designing of selective ALDH1A1 inhibitors to overcome cyclophosphamide resistance: synthesis and biological evaluation

Published:2024 Issue:1 Volume:15 Page:309-321
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Narendra Gera¹,Raju Baddipadige¹,Verma Himanshu¹,Kumar Manoj¹,Jain Subheet Kumar²,Tung Gurleen Kaur³,Thakur Shubham²,Kaur Rasdeep⁴,Kaur Satwinderjeet⁴,Sapra Bharti¹,Silakari Om¹^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, 147002, India

2. Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, India

3. Centre for Basic and Translational Research in Health Sciences, Guru Nanak Dev University, Amritsar, India

4. Department of Botany and Environmental Sciences, Guru Nanak Dev University, Amritsar, India

Abstract

Bioisosteric replacement-based novel benzimidazole derivatives were designed, Synthesized, and evaluated. Combining these ALDH1A1 inhibitors with mafosfamide mitigated cyclophosphamide resistance in A549 and Mia PaCa-2 cell lines.

Funder

Indian Council of Medical Research

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D3MD00543G

Reference26 articles.

1. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family

2. Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1)

3. Drug metabolizing enzymes-associated chemo resistance and strategies to overcome it

4. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy

5. Raloxifene and bazedoxifene as selective ALDH1A1 inhibitors to ameliorate cyclophosphamide resistance: A drug repurposing approach